IVDR: IMPACT AND OPPORTUNITIES FOR A MOLECULAR PATHOLOGY LABORATORY

25 NOVEMBER 2021, 16:00-17:30 CET (UTC +1)

Introduction

On October 14th the EU Commission has proposed a postponement of the Date Of Application of the European In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 (IVDR) which was expected to enter in its full applicability on May 26th, 2022. In spite of this postponement proposal the IVD-R will still apply as of May 26th, next year to certain IVD Devices (Class A) and the Post Market Surveillance requirements will apply to all IVD Devices regardless of their class. This webinar will provide you with a full overview of the impact of the IVD-R and of the applicability of the postponements proposed by the EU Commission.

16:00 WELCOME AND INTRODUCTION
Nicola Normanno
IQN Path President and Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Naples, Italy

16:10 EU IVD-REGULATION 2017/746 – ITS EXPECTED IMPACT FOR LDT PRACTICE
Maurizio Suppo
Principal Consultant, Qarad, European Regulatory Service, Geel, Belgium

16:35 PHARMACEUTICAL INDUSTRY PERSPECTIVE ON IVDR
Claudia Dollins
BMS, US and EFPIA - European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium

16:55 COUNTDOWN TO THE NEW EU IVDR: CHALLENGES FOR PATIENTS
Adela Maghear
ECPC, European Cancer Patient Coalition, Brussels, Belgium

17:15 AUDIENCE FEEDBACK AND PANEL DISCUSSION

17:30 CLOSE

This webinar is supported through an unrestricted educational grant provided by ThermoFisher SCIENTIFIC

View the programme

Registration is free of charge and can be processed online from the website here
For further information, please contact executive@iqnpath.org

PROVIDER AND LOGISTIC SECRETARIAT
MI&T srl - Centro Direzionale Bolomnia Via Guelfa 5 - 40138 Bologna
info@mitcongressi.it - www.mitcongressi.it